Mesa RA - Search Results

1

Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.

Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Naim A, Parasuraman S, Boyle J, Mascarenhas JO. Mesa RA, et al. Cancer. 2017 Feb 1;123(3):449-458. doi: 10.1002/cncr.30325. Epub 2016 Sep 30. Cancer. 2017. PMID: 27690182 Free PMC article.

2

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG. Levine RL, et al. Among authors: mesa ra. Cancer Cell. 2005 Apr;7(4):387-97. doi: 10.1016/j.ccr.2005.03.023. Cancer Cell. 2005. PMID: 15837627 Free article.

3

Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system.

Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Dingli D, et al. Among authors: mesa ra. Cancer. 2006 Feb 1;106(3):623-30. doi: 10.1002/cncr.21644. Cancer. 2006. PMID: 16369987 Free article.

4

Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.

Dingli D, Schwager SM, Mesa RA, Li CY, Dewald GW, Tefferi A. Dingli D, et al. Among authors: mesa ra. Cancer. 2006 May 1;106(9):1985-9. doi: 10.1002/cncr.21868. Cancer. 2006. PMID: 16568439 Free article.

5

Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia.

Gangat N, Wolanskyj AP, Schwager SM, Mesa RA, Tefferi A. Gangat N, et al. Among authors: mesa ra. Cancer. 2006 Jun 1;106(11):2406-11. doi: 10.1002/cncr.21891. Cancer. 2006. PMID: 16628652 Free article.

6

Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic.

Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Mesa RA, et al. Cancer. 2006 Jul 15;107(2):361-70. doi: 10.1002/cncr.22021. Cancer. 2006. PMID: 16770787 Free article.

7

The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, Tan AD, Atherton PJ, Sloan JA, Tefferi A. Mesa RA, et al. Cancer. 2007 Jan 1;109(1):68-76. doi: 10.1002/cncr.22365. Cancer. 2007. PMID: 17123268 Free article.

8

Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution.

Tefferi A, Huang J, Schwager S, Li CY, Wu W, Pardanani A, Mesa RA. Tefferi A, et al. Among authors: mesa ra. Cancer. 2007 May 15;109(10):2083-8. doi: 10.1002/cncr.22630. Cancer. 2007. PMID: 17407134 Free article.

9

Risk factors for leukemic transformation in patients with primary myelofibrosis.

Huang J, Li CY, Mesa RA, Wu W, Hanson CA, Pardanani A, Tefferi A. Huang J, et al. Among authors: mesa ra. Cancer. 2008 Jun 15;112(12):2726-32. doi: 10.1002/cncr.23505. Cancer. 2008. PMID: 18404742 Free article.

10

Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.

Mesa RA. Mesa RA. IDrugs. 2010 Jun;13(6):394-403. IDrugs. 2010. PMID: 20506062

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

435 results

Search Page